Finally, patients with type 2 diabetes on split-mixed or premixed twice-daily insulin regimens who are unable to achieve or maintain target A1C goals may also benefit from conversion to basal-prandial insulin regimens [14]. The gene discussed is INS; the disease is type 2 diabetes mellitus.